Type II mode of JAK2 inhibition and destabilization are potential therapeutic approaches against the ruxolitinib resistance driven myeloproliferative neoplasms

Overview of attention for article published in Frontiers in oncology, July 2024

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (61st percentile)
High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

twitter: 3 X users

Readers on

mendeley: 1 Mendeley

Summary X

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 6,894 followers.

RT @dhurvas2007: New publication update! #collaboration #JAK2 #JAK #Kinases #drugresistance #insilico #Oncology #mutations @HariGorantla2 @…

22 Jul 2024

Reply Repost Favourite

New Research: Type II mode of JAK2 inhibition and destabilization are potential therapeutic approaches against the ruxolitinib resistance driven myeloproliferative neoplasms https://t.co/hH7cLyzKXZ #FrontiersIn #Oncology

18 Jul 2024

Reply Repost Favourite

New publication update! #collaboration #JAK2 #JAK #Kinases #drugresistance #insilico #Oncology #mutations @HariGorantla2 @IOCBPrague @TheBouraLab @FrontiersIn Spl thanks to Dr. Chandrabose Selvaraj @selnikraj Gorantla et al., 2024. Frontiers in Oncology

18 Jul 2024

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.